Stocks Poised for Gain? Pre-Market Watch Eyes Today's Leaders

Don’t want emails from us anymore? Click here to unsubscribe

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


Free Stock Analysis: VectorVest Can Tell You When To Buy or Sell

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

Analyze Any Stock Free

Happening Today

✓ 08:30 AM ET – Core Retail Sales (MoM) (Mar)

✓ 08:30 AM ET – Retail Sales (MoM) (Mar)

✓ 08:30 AM ET – FOMC Member Williams Speaks

✓ 08:30 AM ET – NY Empire State Manufacturing Index (Apr)

✓ 08:30 AM ET – Retail Control (MoM) (Mar)


Stock Futures are pointing to a lower open today, with the Nasdaq down 1.66%.



⬇️ -1.45% 



⬇️ -1.23%



⬇️ -1.66% 


Every sector felt the heat today, with Information Materials taking the biggest hit, down 1.77%.




Consumer Discretionary


-1.61% 🔴

Consumer Staples


-0.91% 🔴



-1.54% 🔴



-1.44% 🔴

Health Care


-1.52% 🔴



-1.07% 🔴



-1.77% 🔴

Real Estate


-1.04% 🔴

Information Technology


-1.64% 🔴

Communication Services


-1.49% 🔴



-0.74% 🔴


Top 5 "Portfolio Supercharging" Stocks - Free Report from Zacks Investment Research

Zacks has a proven track record for picking big winners. And now, our team of experts has hand-selected, from thousands of companies, the 5 stocks they predict they have outsized gain-potential NOW and in the coming year.

Recent recommendations have climbed as high as +288%. In fact, our newest report could point to even bigger gains. These picks will surprise you and current market conditions could make our new recommendations even more profitable. This special arrangement is good for a limited time only.

I urge you to act now!

Unusual Volume

📈 Trio Petroleum Corp. (TPET) jumped 123.28% to $0.52 on a whopping 334.88 million shares traded. The company recently provided operational update for Monterey County Oil Producing Assets.

📈 Investors went wild, sending Beneficient (BENF) stock soaring 40.96% to $0.10 on a massive volume of 121.75 million shares. BENF announced that it has agreed to the financing of liquidity transactions for three separate funds managed by ff Venture Capital, a leading venture capital firm.

📈 Abnormal activity shook PaxMedica Inc (PXMD), pushing it up 103.71% to $0.84 on a whopping 113.92 million shares traded after announcing the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin.

📈 Indonesia Energy Corp Ltd (INDO) stock recently closed 80.29% upper at $4.94 on substantial volume of 56.1 million shares.

📈 Coupang Inc (CPNG) increase by 11.49% in a single trading session, with abnormally high trading volume of 50.93 million shares.


MarketBeat Alert: Strong sell signal just issued for these 20 stocks

Our proprietary research has uncovered a serious red flag for these 20 stocks. Each one has been given a rare SELL signal or downgrade from multiple Wall Street firms. And you'll be shocked at some of the big-name stocks on the list.

Go here now to get free instant access to all 20 stocks to sell.

Premarket Movers

Longeveron Inc. (LGVN) experiences a substantial 47.92% surge in pre-market trading following the closure of $5.2 million public offering.

Soligenix, Inc. (SNGX) sees a significant 70.02% increase, reaching a pre-market price of $0.66 after announcing that the Office of Orphan Products Development of the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient in MarVax™.

SMX (Security Matters) Public Limited Company (SMX) demonstrates a noteworthy 4.72% surge, with a pre-market price of $0.14 after announcing the successful completion of proof of concept for ethical sourcing and authentication of silver in cooperation with SMI.

Pre Market Gainers

Pre Market Change

Pre Market Volume
































A dividend masterpiece

This stock is one of those "diamonds in the rough" that perfectly balances both high income AND high value... AND this company is paying a whopping 12% dividend. And with 8 dividend increases in the past 5 years, it's truly a dividend masterpiece, which is why I just put all of the details (including the ticker symbol) inside a brand new free report.

Click HERE to claim your copy.

Important FDA 

Recently Announced

Johnson & Johnson's (JNJ) Carvykti received FDA approval on April 5, 2024, for expanded use in the treatment of adult patients with relapsed or refractory multiple myeloma who have undergone at least one prior line of therapy.

Bristol-Myers Squibb Co. (BMY) achieved a noteworthy milestone on April 5, 2024, with the FDA's approval of Opdivo in combination with cisplatin-based chemotherapy as a frontline treatment option for adult patients with unresectable or metastatic urothelial carcinoma.

AbbVie's (ABBV) ELAHERE received a significant boost on April 5, 2024, as the FDA granted full approval for certain ovarian cancer patients, converting its accelerated approval in platinum-resistant ovarian cancer to full approval.

Upcoming Announcements

April 2024 heralds three critical FDA determinations that could potentially reshape the treatment landscapes across various patient demographics for biopharmaceutical firms.

ImmunityBio, Inc. (IBRX) is on edge awaiting a pivotal ruling scheduled for April 23rd concerning N-803 plus BCG for high-risk non-muscle-invasive bladder cancer, poised to potentially revolutionize bladder cancer management.

Aquestive Therapeutics Inc. (AQST) eagerly awaits an imminent FDA decision on April 28th regarding Libervant (diazepam) Buccal Film, aimed at mitigating seizure clusters in children aged two to five. This innovation holds significant promise in transforming pediatric epilepsy care through a novel therapeutic approach.

XOMA Corporation (XOMA) stands prepared for a momentous FDA judgment on April 30th concerning tovorafenib, designed to address relapsed or progressive pediatric low-grade glioma (pLGG). This decision carries profound implications in the realm of pediatric oncology, offering a beacon of hope for children navigating this formidable diagnosis.

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.